| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C42H83NO3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C, an mTOR complex regulator, and thereby activates the mTOR signaling pathway. It also alters membrane morphology by inducing formation of a partially interlocked gel phase in the phospholipid bilayer. It can promote the proliferation and migration of keratinocytes to accelerate skin wound healing, and it drives the proliferation and metastasis of gallbladder cancer cells; its serum level can serve as a diagnostic marker for gallbladder cancer[1][2][3]. It is supplied as a white to off-white solid (C42H83NO3, MW 650.11) at 99.92% purity.
Physical & Chemical Properties
| CAS Number | 34435-05-7 |
|---|---|
| Molecular Formula | C42H83NO3 |
| Molecular Weight | 650.11 g/mol |
| Purity | 99.92% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | CCCCCCCCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O |
| Signaling Pathway | PI3K/Akt/mTOR |
| Solubility | In Vitro: THF: 25 mg/mL (38.46 mM; Requires sonication) DMSO: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble) |
| Storage | Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| THF | 25 mg/mL (38.46 mM) | requires sonication |
| DMSO | < 1 mg/mL | insoluble or slightly soluble |
| Ethanol | < 1 mg/mL | insoluble |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
C24-Ceramide (100 μg/mL; 48 h) significantly promotes proliferation and migration of human keratinocytes (HaCaT)[2]. C24-Ceramide (500 μg/mL; 24 h) activates the AKT and ERK1/2 signaling pathways[2]. In gallbladder cancer cells (GBC-SD, NOZ), C24-Ceramide (100 nM; 12 h) promotes proliferation and migration by binding PIP4K2C and activating mTOR signaling, an effect that C6-Ceramide competitively inhibited[3].
Assay of cell viability[2][3]
| Cell Line | HaCaT, GBC-SD, NOZ |
|---|---|
| Concentration | 100 μg/mL for HaCaT cells, 100 nM for GBC-SD, NOZ cells |
| Incubation Time | 24-48 h |
| Result | Promoted cell migration in HaCaT and GBC cells. Enhanced membrane flexibility that facilitates cell movement. |
In Vivo
In the HR-1 hairless mouse skin wound model, C24-Ceramide (4.4 μg/time; topical application; once daily; 10 days) speeds wound closure and promotes epidermal and dermal regeneration and collagen deposition[2]. In a nude mouse subcutaneous xenograft tumor model, C24-Ceramide (10 mg/kg; dietary supplementation; once daily; 3 weeks) promotes growth of gallbladder cancer (GBC-SD cells), as shown by increased tumor volume, weight, and proportion of Ki-67 positive cells[3].
| Animal Model | Male HR-1 hairless mice (6-week-old, 18-20 g), full-thickness skin wound model[2] |
|---|---|
| Dosage | 4.4 μg C24-Ceramide per dose (formulated as C24-LNP in deionized water) |
| Administration | Topical application (10 μL of 1 mg/mL C24-LNP) daily for 10 days |
| Result | Significantly accelerated wound closure. Enhanced re-epithelialization, increased fibroblast proliferation, and improved collagen deposition in the dermis, as confirmed by Masson’s trichrome staining. Activated AKT and ERK1/2 signaling pathways in wound tissues, promoting cell proliferation and migration. |
| Animal Model | Nude mice subcutaneous xenograft model with GBC-SD cells[3] |
|---|---|
| Dosage | 10 mg/kg |
| Administration | Daily oral administration via dietary addition for 3 consecutive weeks |
| Result | Significantly increased tumor size and Ki-67 reactivity in xenograft sections, indicating enhanced cell proliferation. Promoted hepatic metastasis, with higher incidence and size of metastatic lesions compared to control. Activated mTOR signaling through binding to PIP4K2C, which was antagonized by C6-Ceramide co-treatment. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
